Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases in Spain: microbiological and clinical features.

Extended-spectrum β-lactamases (ESBL) of the CTX-M, SHV, and TEM families were recognized in 76 (67%), 31 (27%), and 6 (5%) isolates, respectively, among 162 ESBL-producing Klebsiella pneumoniae (ESBL-Kp) strains obtained in a multicenter study in Spain. Predisposing factors for ESBL-Kp acquisition included invasive procedures, mechanical ventilation, and previous antimicrobial use.

Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't;

This study was partially supported by an unrestricted grant from Wyeth Laboratories (Spain), by the Ministerio de Sanidad y Consumo,Instituto de Salud Carlos III-FEDER, by the Spanish Network for Research in Infectious Diseases (grant REIPI RD06/0008), by FIS(grants PI070190 and INT08/151), and by the Junta de Andalucía(grants 0048/2008, CTS-5209, and 0034/2009). E.R. is supported by IFIMAV, Cantabria, Spain. J.R.-B. reports that he has been a consultant for Wyeth, Merck, and Pfizer, has served as speaker for Wyeth, Merck, Pfizer, AstraZeneca, and GlaxoSmithKline, and has received research support from Merck and Wyeth. A.P. reports that he has been a consultant for Merck and Pfizer, has served as a speaker for Wyeth, AstraZeneca, Merck, and Pfizer, and has received research support from Merck, Pfizer, and Wyeth.L.M.-M. reports that he has been a consultant for Wyeth and Pfizer, has served as speaker for Wyeth, Merck, Pfizer, and Janssen-Cilag, and has received research support from Merck, Wyeth, and Janssen-Cilag.